Core Viewpoint - The announcement by Bohui Innovation regarding the introduction of strategic investor Tongying Group and the capital increase for its subsidiary Hebei Bohui highlights significant developments in the company's growth strategy and operational expansion [2]. Group 1: Strategic Investment - On August 5, 2019, the sixth board of directors of Bohui Innovation approved the introduction of Tongying Group as a strategic investor for its subsidiary Hebei Bohui [2]. - Tongying Group will invest by transferring 120 million shares (72% ownership) of Bohui Biological Pharmaceutical Co., Ltd. and providing cash of 446.75 million yuan for the capital increase [2]. Group 2: Operational Commitments - Tongying Group has committed to ensuring that five plasma collection stations in Luyuan, Yaoan, Shenzhou, Linxi, and Pingdu obtain necessary qualifications and pass inspections within 18 months after the share transfer [2]. - A supplementary agreement was signed in December 2021 to further solidify the investment terms and operational commitments [2]. Group 3: Recent Developments - On February 4, 2026, the eighth board of directors approved a supplementary agreement regarding the approval process for three plasma collection stations in Luyuan, Yaoan, and Pingdu [2]. - This supplementary agreement does not require approval from the company's shareholders [2].